Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its primary product candidate is IMVT-1402, a human monoclonal antibody that inhibits the neonatal fragment crystallizable receptor (FcRn). This therapy is being investigated for multiple autoimmune conditions, including Graves' disease, rheumatoid arthritis, Sjögren's disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company operates as a subsidiary of Roivant Sciences Ltd. and is headquartered in Durham, North Carolina.

Immunovant, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IMVT. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission.

Immunovant operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapies, particularly monoclonal antibodies for autoimmune diseases. The biotechnology industry is characterized by high research intensity, long development timelines, and significant regulatory oversight. Immunovant's work in immunology places it at the intersection of drug discovery and clinical development for chronic autoimmune conditions.

Immunovant, Inc. is headquartered in Durham, North Carolina, United States. The company primarily serves the U.S. market, as indicated by its listing on a U.S. exchange and its focus on developing therapies for autoimmune diseases prevalent in the region. While its clinical trials may involve international sites, its operations and regulatory filings are centered in the United States. As a subsidiary of Roivant Sciences Ltd., it also benefits from a broader network within the biopharmaceutical ecosystem.